BALDAZZI, CARMEN
 Distribuzione geografica
Continente #
NA - Nord America 4.033
EU - Europa 3.209
AS - Asia 2.158
AF - Africa 225
Continente sconosciuto - Info sul continente non disponibili 22
SA - Sud America 11
OC - Oceania 7
Totale 9.665
Nazione #
US - Stati Uniti d'America 4.007
GB - Regno Unito 991
VN - Vietnam 830
SE - Svezia 625
CN - Cina 574
IT - Italia 423
SG - Singapore 410
DE - Germania 379
IN - India 173
IE - Irlanda 137
FR - Francia 133
RU - Federazione Russa 108
UA - Ucraina 81
TG - Togo 79
EE - Estonia 68
ZA - Sudafrica 67
CH - Svizzera 53
BG - Bulgaria 51
JO - Giordania 50
FI - Finlandia 49
NG - Nigeria 40
GR - Grecia 37
IR - Iran 37
CI - Costa d'Avorio 34
BE - Belgio 29
CA - Canada 25
EU - Europa 21
TR - Turchia 15
ID - Indonesia 11
JP - Giappone 8
PL - Polonia 8
AU - Australia 7
HK - Hong Kong 7
UZ - Uzbekistan 7
AT - Austria 6
BR - Brasile 6
KR - Corea 6
LB - Libano 5
NL - Olanda 5
SC - Seychelles 5
ES - Italia 4
PH - Filippine 4
RO - Romania 4
CL - Cile 3
HR - Croazia 3
MK - Macedonia 3
TW - Taiwan 3
LT - Lituania 2
LU - Lussemburgo 2
MY - Malesia 2
NO - Norvegia 2
PK - Pakistan 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
GE - Georgia 1
IL - Israele 1
IQ - Iraq 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
PA - Panama 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
Totale 9.665
Città #
Southend 935
Dong Ket 589
Chandler 470
Fairfield 417
Singapore 353
Ashburn 265
Ann Arbor 257
Houston 237
Wilmington 235
Seattle 200
Woodbridge 196
Princeton 165
Cambridge 153
Dublin 137
Santa Clara 136
Boardman 108
Beijing 97
Nanjing 80
Lomé 79
Westminster 78
Padova 71
Bologna 69
New York 63
Medford 55
Amman 50
Berlin 50
Sofia 48
Bern 46
Abeokuta 39
Bremen 39
Shenyang 36
Jinan 35
Abidjan 34
Helsinki 34
Saint Petersburg 34
Hebei 31
Nanchang 29
Turin 29
Brussels 28
Florence 24
Jacksonville 23
Changsha 22
San Diego 22
Milan 21
Redwood City 21
Falls Church 19
Hangzhou 18
Mountain View 17
Paris 17
Guangzhou 15
Lappeenranta 15
Los Angeles 14
Istanbul 13
Tianjin 13
Jiaxing 12
Norwalk 12
Haikou 11
Jakarta 11
Tehran 11
Zhengzhou 11
Busseto 10
Castelfranco Emilia 10
Redmond 10
Toronto 10
Fuzhou 9
Hyderabad 9
Rome 9
Andover 8
Athens 8
Bühl 8
Monmouth Junction 8
Mülheim 8
Shanghai 8
Zanjan 8
Leawood 7
Frankfurt am Main 6
Ningbo 6
North York 6
Olalla 6
Taiyuan 6
Taizhou 6
Vienna 6
Bo 5
Dearborn 5
Hong Kong 5
Kraków 5
Kunming 5
Lanzhou 5
Mahé 5
Moscow 5
Sacramento 5
Washington 5
Augusta 4
Des Moines 4
Grafing 4
Phoenix 4
Romainville 4
Shijiazhuang 4
Tappahannock 4
Tokyo 4
Totale 6.603
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 282
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 237
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 228
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 227
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 221
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 218
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 206
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 194
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 188
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 187
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 175
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 174
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 172
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 167
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 159
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 153
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 148
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 148
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 147
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 145
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 144
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 140
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 139
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 132
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 132
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 130
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 130
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 129
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 127
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 124
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 123
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 122
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 122
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 122
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 120
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 120
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 119
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 118
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 116
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 115
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 112
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 112
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 109
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 109
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 109
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 107
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 105
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 105
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 104
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 103
Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP) 102
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 100
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience 98
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 98
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: the Bologna experience 97
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 96
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 95
Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL). 95
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 92
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 92
You have accessA New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 92
IKZF1 (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME 89
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 88
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 87
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 87
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 84
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 83
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 82
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 78
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 78
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 75
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) ARRAYS IDENTIFIED FREQUENT GENOMIC ABNORMALITIES IN GENES INVOLVED IN DRUG TRANSPORT AND INHIBITION OF APOPTOSIS IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS 75
IKZF1 (IKAROS) DELETIONS ARE INDEPENDENT ON THE PHILADELPHIA CHROMOSOME AND ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 69
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 69
IDENTIFICATION OF FREQUENT GENOMIC ABNORMALITIES IN ADULT ACUTE MYELOID LEUKEMIA PATIENTS USING SINGLE NUCLEOTIDE POLYMORPHISM ARRAYS 65
IKZF1 (IKAROS) DELETIONS ARE A CENTRAL EVENT IN THE PATHOGENESIS OF BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 64
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 62
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 53
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 30
Totale 9.908
Categoria #
all - tutte 24.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.649


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.337 0 0 0 0 0 195 234 228 294 162 120 104
2020/20211.604 209 55 42 33 31 66 34 94 120 57 74 789
2021/20221.862 252 43 101 180 179 103 37 95 95 150 328 299
2022/20231.979 220 311 118 258 134 159 47 108 329 49 153 93
2023/2024589 23 74 28 68 39 149 36 52 21 31 38 30
2024/2025975 71 297 177 125 241 64 0 0 0 0 0 0
Totale 9.908